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We have recently demonstrated that Cftr knockout (Cftr−/−) and F508del-CFTR
(DF/DF) mice exhibit structural abnormalities of the trachea characterized by
disrupted or incomplete cartilage rings. Such defects may lead to upper or lower
segmental constriction of the trachea. We, thus, investigated whether structural
alterations in the tracheal area which contains sites of high CFTR expression, may
contribute to tracheal and ventilatory dysfunction in cystic ﬁbrosis (CF).
To test this hypothesis, we examined 1) the contractile response to carbachol (CCh)
of the proximal and distal portions of trachea in Cftr−/− and DF/DF mice compared
to their respective controls; 2) the tracheal relaxation in response to salbutamol
of precontracted tracheal segments in Cftr−/− and Cftr+/+ mice; 3) the pattern of
breathing in Cftr−/− and Cftr+/+ mice by using whole-body plethysmography.
Our data show in Cftr−/− mice a decreased contractile response to CCh in proximal
trachea, and an impaired relaxation in response to salbutamol in both tracheal
segments. In DF/DF mice, distal trachea was less sensitive to CCh than proximal
trachea. Analysis of ventilation showed a lower breathing rate in Cftr−/− than in
Cftr+/+ mice due to a marked increase in both inspiratory and expiratory times.
We conclude that CFTR-deﬁcient mice exhibiting abnormal tracheal architecture
display tracheal dysfunction and altered respiratory airﬂow which may contribute
to the pathogenesis of airway disease in CF patients.
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The vectorial transport of ions and water across epithelial cells depends on the
co-ordination of the ion ﬂuxes at the apical and basolateral membranes with
energy supply. We provide the ﬁrst evidence for a regulation by the 5′-AMP-
activated protein kinase (AMPK) of the KCa3.1 channel expressed at the basolateral
membrane of a large variety of epithelial cells. Co-immunoprecipitation and pull-
down experiments showed that the C-terminal region of KCa3.1 (Leu345 to Ala400)
interacts with the a1 and g1 subunits of AMPK. AMPK-g1 and KCa3.1 were also
found to colocalized at the plasma membrane of HEK-293 cells. A decrease in
KCa3.1 activity was observed in inside-out patch clamp experiments following
the addition of AMP at a ﬁxed ATP concentration (1 mM) with half inhibition
at 140mM. AMP-dependent inhibition was not observed in the presence of Ara-
A (1 mM) an AMPK inhibitor. Coexpressing KCa3.1 in HEK-293 cells with the
dominant negative mutant R299G of AMPK-g1 resulted in an increase of the cells
with a low response to AMP from 5% in control to 50% with the g1 mutant.
Finally, we show that the activation of AMPK by the membrane permeant AMPK
activator AICAR causes a decrease of the KCa3.1-mediated short circuit currents
in bronchial epithelial cell monolayers. The current decrease initiated by AICAR
was reversed by coincubation with 10mM Compound-C conﬁrming a regulation of
KCa3.1 by AMPK in a functional epithelium. Altogether our results point toward
a metabolic control of KCa3.1 through AMPK activation.
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Introduction: Osteoporosis is a common and serious complication of cystic ﬁbrosis
(CF), and alteration of CFTR function in bone cells may contribute. Inactivation of
the CFTR gene in mice causes severe osteopenia, and in adults with CF the DF508
mutation is an independent risk factor for low bone mineral density.
Methods: Osteoblastic cell lines (MG63 and SaOS), primary human osteoblasts and
human osteoclasts cultured from peripheral blood mononuclear cells were examined
for the expression of CFTR protein by Western blotting and immunoﬂuorescence
using a mouse anti-human CFTR (C-terminus) monoclonal antibody (clone 24).
Results: Primary human osteoblasts and osteoblastic cell lines were found
to express mature (fully glycosylated 180 kD), ER-glycosylated (150 kD) and
newly-synthesized non-glycosylated (130 kD) CFTR. Non-glycosylated and ER-
glycosylated CFTR was detected in Western blots of osteoclast lysates, but minimal
(<0.5% of total CFTR) fully glycosylated protein was found in these cells.
Immunoﬂuorescence suggested a cytoplasmic rather than membrane-associated
distribution in all cell types examined.
Conclusion: CFTR protein is present in human osteoblasts and osteoclasts, although
in the latter cell type the expression of mature, fully glycosylated CFTR is limited.
The functional signiﬁcance of these ﬁndings and their implication for CF-associated
bone disease remain to be determined.
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Lung inﬂammation and airway remodeling are hallmarks of CF lung disease. We
investigated transcriptional responses to epithelial injury in a mouse model of CF
(F508del, Cftrtm1eur) using a quantitative PCR array of 56 genes differentially
expressed after naphthalene injury of distal airways. Homozygous normal and
mutant age matched littermates were treated in parallel with Naphthalene or carrier
as control (N = 4×12). In this gene cluster, signiﬁcant (P< 0.05) over-expression
of acute phase proteins (Orm1, Serpina3n, Ecm1, Lcn2) and metalloproteinases
(Mmp8, Mmp9) was observed in unchallenged mutant animals compared to normal.
Furthermore, several modulators of tissue repair were upregulated in mutant mice
both before and after injury (Igfbp5, Il6st, Tnfrsf12, Egr1, Adam10, Adam17). After
naphthalene injury, EGF receptor agonists Amphiregulin, Epiregulin and Heparin
binding EGF were strongly induced in normal and mutant animals, correlating with
an increase of major extracellular matrix (ECM) mRNA’s (Co1a1, Col3a1, Elastin).
Whereas expression levels were substantially reduced in normal animals seven days
after injury, in CF mutant animals two to three fold higher levels were observed
for these three genes at day seven (P< 0.04).
Conclusions: Our data support and extend the notion that inﬂammation and
activation of tissue remodeling pathways occurs in unchallenged pathogen free
F508del mice. This would explain the sustained ECM mRNA production in CF
mouse lung after injury, suggesting an inherent tendency towards ﬁbrosis in CF
lungs, and providing new targets for therapy of irreversible lung damage in CF.
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